NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
March 21, 2023 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39th Annual Meeting on March 23 - 26 in...
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
March 14, 2023 07:05 ET
|
Virios Therapeutics
ATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to...
Anticonvulsant Drugs Market to Surpass US$ 8,030.4 Million by 2030, Says Coherent Market Insights (CMI)
February 22, 2023 09:15 ET
|
CMI
Burlingame, Feb. 22, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global anticonvulsant drugs market is estimated to be valued at US$ 6,757.8 in 2022 and is expected to...
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
January 05, 2023 07:00 ET
|
Virios Therapeutics
ATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat...
NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
November 08, 2022 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on...
NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
November 03, 2022 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., Nov. 03, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell® Fibromyalgia device through the Pathfinder Program. Quell...
Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting
September 20, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American...
NeuroMetrix Reports that Quell® Wearable Neuromodulation Device has Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia
May 19, 2022 09:00 ET
|
NeuroMetrix, Inc.
WOBURN, Mass., May 19, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced U.S. Food and Drug Administration (FDA) De Novo authorization to market the Quell neuromodulation...
Exagen Inc. Reports Fourth Quarter and Full Year 2021 Results
March 22, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today reported financial results for the fourth quarter and full year...
Exagen Inc. to Participate in the 2022 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
February 02, 2022 16:05 ET
|
Exagen Inc.
SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health,...